{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:49:59Z","timestamp":1790714999495,"version":"4.1.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05541-w","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T02:26:35Z","timestamp":1763951195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neuroprotective Attributes of Gut-derived Urolithins in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"63","author":[{"given":"Sushila","family":"Chhetry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhideep","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubina","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallab","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Tapias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupom","family":"Borah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"5541_CR1","doi-asserted-by":"publisher","unstructured":"Darden L (2007) Mechanisms and models. The Cambridge Companion to the Philosophy of Biology 39:139\u2013159. https:\/\/doi.org\/10.1017\/CCOL9780521851282.008","DOI":"10.1017\/CCOL9780521851282.008"},{"key":"5541_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Primers 3:1\u201321. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"key":"5541_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/247467","volume":"2011","author":"T Farooqui","year":"2011","unstructured":"Farooqui T, Farooqui AA (2011) Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson\u2019s disease. Parkinsons Dis 2011:1\u20139. https:\/\/doi.org\/10.4061\/2011\/247467","journal-title":"Parkinsons Dis"},{"key":"5541_CR4","doi-asserted-by":"publisher","first-page":"10813","DOI":"10.1073\/pnas.152339799","volume":"99","author":"C Lo Bianco","year":"2002","unstructured":"Lo Bianco C, Ridet JL, Schneider BL et al (2002) \u0391-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson\u2019s disease. Proc Natl Acad Sci U S A 99:10813\u201310818. https:\/\/doi.org\/10.1073\/pnas.152339799","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5541_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00702-023-02660-3","volume":"130","author":"KA Jellinger","year":"2023","unstructured":"Jellinger KA (2023) Morphological characteristics differentiate dementia with Lewy bodies from Parkinson disease with and without dementia. J Neural Transm 130:891\u2013904. https:\/\/doi.org\/10.1007\/s00702-023-02660-3","journal-title":"J Neural Transm"},{"issue":"S1","key":"5541_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/jnc.13731","volume":"139","author":"A Bose","year":"2016","unstructured":"Bose A, Beal MF (2016) Mitochondrial dysfunction in Parkinson\u2019s disease. J Neurochem 139(S1):216\u2013231. https:\/\/doi.org\/10.1111\/jnc.13731","journal-title":"J Neurochem"},{"key":"5541_CR7","doi-asserted-by":"publisher","unstructured":"Pajares MI, Rojo A, Manda G, Bosc\u00e1 L, Cuadrado A (2020) Inflammation in parkinson's disease: mechanisms and therapeutic implications. Cells 9(7):1687. https:\/\/doi.org\/10.3390\/cells9071687","DOI":"10.3390\/cells9071687"},{"key":"5541_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3969\/j.issn.1673-5374.2012.02.011","volume":"7","author":"L Zhang","year":"2012","unstructured":"Zhang L, Dong Y, Xu X, Xu Z (2012) The role of autophagy in Parkinson\u2019s disease. Neural Regen Res 7:141\u2013145. https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2012.02.011","journal-title":"Neural Regen Res"},{"key":"5541_CR9","doi-asserted-by":"crossref","unstructured":"Nechushtai L, Frenkel D, & Pinkas-Kramarski R (2023) Autophagy in Parkinson\u2019s disease. Biomolecules 13(10):1435","DOI":"10.3390\/biom13101435"},{"key":"5541_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0303-8467(98)00009-2","volume":"100","author":"BAJ Veldman","year":"1998","unstructured":"Veldman BAJ, Wijn AM, Knoers N et al (1998) Genetic and environmental risk factors in Parkinson\u2019s disease. Clin Neurol Neurosurg 100:15\u201326. https:\/\/doi.org\/10.1016\/S0303-8467(98)00009-2","journal-title":"Clin Neurol Neurosurg"},{"key":"5541_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 36:1\u201312. https:\/\/doi.org\/10.1016\/j.cger.2019.08.002","journal-title":"Clin Geriatr Med"},{"key":"5541_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-38248-4","volume":"14","author":"B Huang","year":"2023","unstructured":"Huang B, Chau SWH, Liu Y et al (2023) Gut microbiome dysbiosis across early Parkinson\u2019s disease, REM sleep behavior disorder and their first-degree relatives. Nat Commun 14:1\u201313. https:\/\/doi.org\/10.1038\/s41467-023-38248-4","journal-title":"Nat Commun"},{"key":"5541_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2021.615075","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang Y, Liao J, Liu X et al (2021) Review: the role of intestinal dysbiosis in Parkinson\u2019s disease. Front Cell Infect Microbiol 11:1\u201313. https:\/\/doi.org\/10.3389\/fcimb.2021.615075","journal-title":"Front Cell Infect Microbiol"},{"key":"5541_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.937555","volume":"13","author":"M Zhu","year":"2022","unstructured":"Zhu M, Liu X, Ye Y et al (2022) Gut microbiota: a novel therapeutic target for Parkinson\u2019s disease. Front Immunol 13:1\u201319. https:\/\/doi.org\/10.3389\/fimmu.2022.937555","journal-title":"Front Immunol"},{"key":"5541_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1287\/isre.1090.0265","volume":"22","author":"PJ Bateman","year":"2011","unstructured":"Bateman PJ, Gray PH, Butler BS (2011) The impact of community commitment on participation in online communities. Inf Syst Res 22:841\u2013854. https:\/\/doi.org\/10.1287\/isre.1090.0265","journal-title":"Inf Syst Res"},{"key":"5541_CR16","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/j.1471-4159.2007.04567.x","volume":"101","author":"I Rite","year":"2007","unstructured":"Rite I, Machado A, Cano J, Venero JL (2007) Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem 101:1567\u20131582. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.04567.x","journal-title":"J Neurochem"},{"issue":"24","key":"5541_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417557","volume":"24","author":"MH Janeiro","year":"2023","unstructured":"Janeiro MH, Solas M, Orbe J, Rodr\u00edguez JA, de Sanchez Muniain L, Escalada P, Yip PK, Ramirez MJ (2023) Trimethylamine N-oxide as a mediator linking peripheral to central inflammation: an in vitro study. Int J Mol Sci 24(24):17557. https:\/\/doi.org\/10.3390\/ijms242417557","journal-title":"Int J Mol Sci"},{"issue":"7","key":"5541_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cells12071012","volume":"12","author":"S Isik","year":"2023","unstructured":"Isik S, Yeman Kiyak B, Akbayir R, Seyhali R, Arpaci T (2023) Microglia mediated neuroinflammation in Parkinson\u2019s disease. Cells 12(7):1012. https:\/\/doi.org\/10.3390\/cells12071012","journal-title":"Cells"},{"key":"5541_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-023-02782-1","volume":"20","author":"J Yu","year":"2023","unstructured":"Yu J, Meng J, Qin Z et al (2023) Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson\u2019s disease. J Neuroinflammation 20:1\u201314. https:\/\/doi.org\/10.1186\/s12974-023-02782-1","journal-title":"J Neuroinflammation"},{"key":"5541_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104887","volume":"98","author":"E Huh","year":"2023","unstructured":"Huh E, Choi JG, Choi Y et al (2023) P. mirabilis-derived pore-forming haemolysin, HpmA drives intestinal alpha-synuclein aggregation in a mouse model of neurodegeneration. EBioMedicine 98:104887. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104887","journal-title":"EBioMedicine"},{"key":"5541_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-025-01410-0","volume":"25","author":"D Lin","year":"2025","unstructured":"Lin D, Howard A, Raihane AS et al (2025) Traumatic brain injury and gut microbiome: the role of the gut-brain axis in neurodegenerative processes. Curr Neurol Neurosci Rep 25:23. https:\/\/doi.org\/10.1007\/s11910-025-01410-0","journal-title":"Curr Neurol Neurosci Rep"},{"key":"5541_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nm.4132","volume":"22","author":"D Ryu","year":"2016","unstructured":"Ryu D, Mouchiroud L, Andreux PA et al (2016) Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med 22:879\u2013888. https:\/\/doi.org\/10.1038\/nm.4132","journal-title":"Nat Med"},{"key":"5541_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/nu15183884","volume":"15","author":"L An","year":"2023","unstructured":"An L, Lu Q, Wang K, Wang Y (2023) Urolithins: a prospective alternative against brain aging. Nutrients 15:3884. https:\/\/doi.org\/10.3390\/nu15183884","journal-title":"Nutrients"},{"key":"5541_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12071479","volume":"12","author":"O Wojciechowska","year":"2023","unstructured":"Wojciechowska O, Kujawska M (2023) Urolithin A in Health and Diseases: Prospects for Parkinson\u2019s disease management. Antioxidants 12:1479. https:\/\/doi.org\/10.3390\/antiox12071479","journal-title":"Antioxidants"},{"key":"5541_CR25","doi-asserted-by":"publisher","first-page":"10476","DOI":"10.1021\/jf0723864","volume":"55","author":"JC Esp\u00edn","year":"2007","unstructured":"Esp\u00edn JC, Gonz\u00e1lez-Barrio R, Cerd\u00e1 B et al (2007) Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J Agric Food Chem 55:10476\u201310485. https:\/\/doi.org\/10.1021\/jf0723864","journal-title":"J Agric Food Chem"},{"key":"5541_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/270418","volume":"2013","author":"JC Esp\u00edn","year":"2013","unstructured":"Esp\u00edn JC, Larrosa M, Garc\u00eda-Conesa MT, Tom\u00e1s-Barber\u00e1n F (2013) Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: the evidence so far. Evidence-based Complement Altern Medicine 2013:1. https:\/\/doi.org\/10.1155\/2013\/270418","journal-title":"Evidence-based Complement Altern Medicine"},{"key":"5541_CR27","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.foodres.2011.04.027","volume":"44","author":"JM Landete","year":"2011","unstructured":"Landete JM (2011) Ellagitannins, ellagic acid and their derived metabolites: a review about source, metabolism, functions and health. Food Res Int 44:1150\u20131160. https:\/\/doi.org\/10.1016\/j.foodres.2011.04.027","journal-title":"Food Res Int"},{"key":"5541_CR28","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.1021\/jf5024615","volume":"62","author":"FA Tom\u00e1s-Barber\u00e1n","year":"2014","unstructured":"Tom\u00e1s-Barber\u00e1n FA, Garc\u00eda-Villalba R, Gonz\u00e1lez-Sarr\u00edas A et al (2014) Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. J Agric Food Chem 62:6535\u20136538. https:\/\/doi.org\/10.1021\/jf5024615","journal-title":"J Agric Food Chem"},{"key":"5541_CR29","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Villalba R, Gim\u00e9nez-Bastida JA, Cort\u00e9s-Mart\u00edn A et al (2022) Urolithins: a comprehensive update on their metabolism, bioactivity, and associated gut microbiota. Mol Nutr Food Res 66. https:\/\/doi.org\/10.1002\/mnfr.202101019","DOI":"10.1002\/mnfr.202101019"},{"key":"5541_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/00498258009033752","volume":"10","author":"B Doyle","year":"1980","unstructured":"Doyle B, Griffiths LA (1980) The metabolism of ellagic acid in the rat. Xenobiotica 10:247\u2013256. https:\/\/doi.org\/10.3109\/00498258009033752","journal-title":"Xenobiotica"},{"key":"5541_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2426614","volume":"16","author":"S Alqudah","year":"2024","unstructured":"Alqudah S, Claesen J (2024) Mechanisms of gut bacterial metabolism of dietary polyphenols into bioactive compounds. Gut Microbes 16:2426614. https:\/\/doi.org\/10.1080\/19490976.2024.2426614","journal-title":"Gut Microbes"},{"issue":"20","key":"5541_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/nu15204441","volume":"15","author":"H Zhao","year":"2023","unstructured":"Zhao H, Song G, Zhu H, Qian He, Pan X, Song X, Xie Y, Liu C (2023) Pharmacological effects of urolithin A and its role in muscle health and performance: current knowledge and prospects. Nutrients 15(20):4441. https:\/\/doi.org\/10.3390\/nu15204441","journal-title":"Nutrients"},{"key":"5541_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnut.2021.647582","volume":"8","author":"SA Al-Harbi","year":"2021","unstructured":"Al-Harbi SA, Abdulrahman AO, Zamzami MA, Khan MI (2021) Urolithins: the gut based polyphenol metabolites of ellagitannins in cancer prevention, a review. Front Nutr 8:1\u201315. https:\/\/doi.org\/10.3389\/fnut.2021.647582","journal-title":"Front Nutr"},{"issue":"1","key":"5541_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-023-09112-x","volume":"51","author":"NOM Albuthyab","year":"2024","unstructured":"Albuthyab NOM, Hosseini H, Homayouni Tabrizi M, Kharaghani M, Saghravanian SS (2024) The urolithin B nanomicellar delivery system as an efficient selective anticancer compound. Mol Biol Rep 51(1):85. https:\/\/doi.org\/10.1007\/s11033-023-09112-x","journal-title":"Mol Biol Rep"},{"key":"5541_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines9020192","volume":"9","author":"AM Toney","year":"2021","unstructured":"Toney AM, Fox D, Chaidez V et al (2021) Immunomodulatory role of urolithin A on metabolic diseases. Biomedicines 9:1\u201318. https:\/\/doi.org\/10.3390\/biomedicines9020192","journal-title":"Biomedicines"},{"key":"5541_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s11626-024-01005-y","author":"S Li","year":"2025","unstructured":"Li S, Zhang Y, Zhang T et al (2025) Urolithin B suppresses phenotypic switch in vascular smooth muscle cells induced by PDGF - BB via inhibiting the PI3K - AKT pathway. In Vitro Cell Dev Biol - Anim. https:\/\/doi.org\/10.1007\/s11626-024-01005-y","journal-title":"In Vitro Cell Dev Biol - Anim"},{"key":"5541_CR37","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1111\/bph.14821","volume":"176","author":"M Bayle","year":"2019","unstructured":"Bayle M, Neasta J, Dall\u2019Asta M et al (2019) The ellagitannin metabolite urolithin C is a glucose-dependent regulator of insulin secretion through activation of L-type calcium channels. Br J Pharmacol 176:4065\u20134078. https:\/\/doi.org\/10.1111\/bph.14821","journal-title":"Br J Pharmacol"},{"key":"5541_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41387-023-00253-3","volume":"13","author":"C Luo","year":"2023","unstructured":"Luo C, Hou C, Yang D et al (2023) Urolithin C alleviates pancreatic \u03b2-cell dysfunction in type 1 diabetes by activating Nrf2 signaling. Nutr Diabetes 13:1\u201310. https:\/\/doi.org\/10.1038\/s41387-023-00253-3","journal-title":"Nutr Diabetes"},{"key":"5541_CR39","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/mnfr.201500470","volume":"59","author":"C Giorgio","year":"2015","unstructured":"Giorgio C, Mena P, Del Rio D et al (2015) The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells. Mol Nutr Food Res 59:2155\u20132167. https:\/\/doi.org\/10.1002\/mnfr.201500470","journal-title":"Mol Nutr Food Res"},{"key":"5541_CR40","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1021\/acschemneuro.3c00070","volume":"14","author":"R Roy","year":"2023","unstructured":"Roy R, Paul R, Bhattacharya P, Borah A (2023) Combating dopaminergic neurodegeneration in Parkinson\u2019s disease through nanovesicle technology. ACS Chem Neurosci 14:2830\u20132848","journal-title":"ACS Chem Neurosci"},{"key":"5541_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pneurobio.2017.04.006","volume":"156","author":"AO Pires","year":"2017","unstructured":"Pires AO, Teixeira FG, Mendes-Pinheiro B, Serra SC, Sousa N, Salgado AJ (2017) Old and new challenges in Parkinson\u2019s disease therapeutics. Prog Neurobiol 156:69\u201389. https:\/\/doi.org\/10.1016\/j.pneurobio.2017.04.006","journal-title":"Prog Neurobiol"},{"key":"5541_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/9783527629480.ch2","volume-title":"Parkinson disease: a health policy perspective","author":"W Martin","year":"2010","unstructured":"Martin W (2010) Clinical features of Parkinson disease. Parkinson disease: a health policy perspective. Wiley, pp 9\u201320. https:\/\/doi.org\/10.1002\/9783527629480.ch2"},{"key":"5541_CR43","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J (2008) Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368\u2013376. https:\/\/doi.org\/10.1136\/jnnp.2007.131045","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5541_CR44","doi-asserted-by":"publisher","unstructured":"Erro R, Stamelou M (2017) The motor syndrome of parkinson's disease.\u00a0Int Rev Neurobiol\u00a0132: 25\u201332. https:\/\/doi.org\/10.1016\/bs.irn.2017.01.004","DOI":"10.1016\/bs.irn.2017.01.004"},{"key":"5541_CR45","doi-asserted-by":"publisher","unstructured":"eite Silva ABR, Gon\u00e7alves de Oliveira RW, Di\u00f3genes GP et al (2023) Premotor, nonmotor and motor symptoms of Parkinson\u2019s disease: a new clinical state of the art. Ageing Res Rev 84:101834. https:\/\/doi.org\/10.1016\/j.arr.2022.101834","DOI":"10.1016\/j.arr.2022.101834"},{"key":"5541_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1478-811X-11-34","volume":"11","author":"J Meiser","year":"2013","unstructured":"Meiser J, Weindl D, Hiller K (2013) Complexity of dopamine metabolism. Cell Commun Signal 11:1\u201318. https:\/\/doi.org\/10.1186\/1478-811X-11-34","journal-title":"Cell Commun Signal"},{"key":"5541_CR47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neuint.2017.01.007","volume":"105","author":"A Stefani","year":"2017","unstructured":"Stefani A, Pierantozzi M, Olivola E et al (2017) Homovanillic acid in CSF of mild stage Parkinson\u2019s disease patients correlates with motor impairment. Neurochem Int 105:58\u201363. https:\/\/doi.org\/10.1016\/j.neuint.2017.01.007","journal-title":"Neurochem Int"},{"key":"5541_CR48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.mehy.2018.06.009","volume":"117","author":"MK Mazumder","year":"2018","unstructured":"Mazumder MK, Paul R, Phukan BC, Dutta A, Chakrabarty J, Bhattacharya P, Borah A (2018) Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson\u2019s disease. Med Hypotheses 117:54\u201358. https:\/\/doi.org\/10.1016\/j.mehy.2018.06.009","journal-title":"Med Hypotheses"},{"key":"5541_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/920953","author":"P Mu\u00f1oz","year":"2012","unstructured":"Mu\u00f1oz P, Huenchuguala S, Paris I, Segura-Aguilar J (2012) Dopamine oxidation and autophagy. Parkinsons Dis. https:\/\/doi.org\/10.1155\/2012\/920953","journal-title":"Parkinsons Dis"},{"key":"5541_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-00885-5","author":"JR Bedarf","year":"2025","unstructured":"Bedarf JR, Romano S, Heinzmann SS, Duncan A (2025) A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson\u2019s disease check for updates. NPJ Parkinsons Dis. https:\/\/doi.org\/10.1038\/s41531-025-00885-5","journal-title":"NPJ Parkinsons Dis"},{"key":"5541_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-019-0100-x","volume":"5","author":"S Weis","year":"2019","unstructured":"Weis S, Schwiertz A, Unger MM et al (2019) Effect of Parkinson\u2019s disease and related medications on the composition of the fecal bacterial microbiota. NPJ Parkinsons Dis 5:1\u20139. https:\/\/doi.org\/10.1038\/s41531-019-0100-x","journal-title":"NPJ Parkinsons Dis"},{"key":"5541_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012289","volume":"23","author":"A Varesi","year":"2022","unstructured":"Varesi A, Campagnoli LIM, Fahmideh F et al (2022) The interplay between gut microbiota and Parkinson\u2019s disease: implications on diagnosis and treatment. Int J Mol Sci 23:12289. https:\/\/doi.org\/10.3390\/ijms232012289","journal-title":"Int J Mol Sci"},{"key":"5541_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2025.128077","volume":"293","author":"W Zhu","year":"2025","unstructured":"Zhu W, Hu Y, Shi Y, Bao H, Cheng X, Mi Jiang, Peng Z, Song J et al (2025) Sleep deprivation accelerates Parkinson\u2019s disease via modulating gut microbiota associated microglial activation and oxidative stress. Microbiol Res 293:128077. https:\/\/doi.org\/10.1016\/j.micres.2025.128077","journal-title":"Microbiol Res"},{"key":"5541_CR54","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2276296","volume":"15","author":"D Liang","year":"2023","unstructured":"Liang D, Liu H, Jin R et al (2023) Escherichia coli triggers \u03b1-synuclein pathology in the LRRK2 transgenic mouse model of PD. Gut Microbes 15:2276296. https:\/\/doi.org\/10.1080\/19490976.2023.2276296","journal-title":"Gut Microbes"},{"key":"5541_CR55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jneuroim.2019.01.004","volume":"328","author":"S Roy Sarkar","year":"2019","unstructured":"Roy Sarkar S, Banerjee S (2019) Gut microbiota in neurodegenerative disorders. J Neuroimmunol 328:98\u2013104. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.01.004","journal-title":"J Neuroimmunol"},{"key":"5541_CR56","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s12264-023-01123-9","volume":"40","author":"WX Duan","year":"2024","unstructured":"Duan WX, Wang F, Liu JY, Liu CF (2024) Relationship between short-chain fatty acids and Parkinson\u2019s disease: a review from pathology to clinic. Neurosci Bull 40:500\u2013516. https:\/\/doi.org\/10.1007\/s12264-023-01123-9","journal-title":"Neurosci Bull"},{"key":"5541_CR57","doi-asserted-by":"publisher","unstructured":"Shabbir F, Patel A, Mattison C et al (2013) Effect of diet on serotonergic neurotransmission in depression. Neurochem Int 62(3):324\u2013329. https:\/\/doi.org\/10.1016\/j.neuint.2012.12.014","DOI":"10.1016\/j.neuint.2012.12.014"},{"issue":"5","key":"5541_CR58","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/ana.25236","volume":"83","author":"V Kotagal","year":"2018","unstructured":"Kotagal V, Spino C, Bohnen NI, Koeppe R, Albin RL (2018) Serotonin, \u03b2-amyloid, and cognition in Parkinson disease. Ann Neurol 83(5):994\u20131002. https:\/\/doi.org\/10.1002\/ana.25236","journal-title":"Ann Neurol"},{"issue":"7","key":"5541_CR59","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1097\/HC9.0000000000000484","volume":"8","author":"R Zhang","year":"2024","unstructured":"Zhang R, Yan Z, Zhong H, Luo R, Liu W, Xiong S, Liu Q, Liu Mi (2024) Gut microbial metabolites in MASLD: implications of mitochondrial dysfunction in the pathogenesis and treatment. Hepatol Commun 8(7):3745\u20133758. https:\/\/doi.org\/10.1097\/HC9.0000000000000484","journal-title":"Hepatol Commun"},{"key":"5541_CR60","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1007\/s12035-016-0145-3","volume":"54","author":"I Fonseca","year":"2017","unstructured":"Fonseca I, Gordino G, Moreira S et al (2017) Tauroursodeoxycholic acid protects against mitochondrial dysfunction and cell death via mitophagy in human neuroblastoma cells. Mol Neurobiol 54:6107\u20136119. https:\/\/doi.org\/10.1007\/s12035-016-0145-3","journal-title":"Mol Neurobiol"},{"issue":"7","key":"5541_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70541","volume":"31","author":"Y Du","year":"2025","unstructured":"Du Y, Wang L, Cui Y, Xu X, Zhang M, Li Y, Gao T, Gao D et al (2025) Effect of probiotics supplementation on REM sleep behavior disorder and motor symptoms in Parkinson\u2019s disease: a pilot study. CNS Neurosci Ther 31(7):e70541. https:\/\/doi.org\/10.1111\/cns.70541","journal-title":"CNS Neurosci Ther"},{"key":"5541_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118058","volume":"187","author":"AK Navin","year":"2025","unstructured":"Navin AK, Rejani CT, Chandrasekaran B, Tyagi A (2025) Urolithins: emerging natural compound targeting castration-resistant prostate cancer (CRPC). Biomed Pharmacother 187:118058. https:\/\/doi.org\/10.1016\/j.biopha.2025.118058","journal-title":"Biomed Pharmacother"},{"key":"5541_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.tifs.2024.104622","volume":"151","author":"Z Hua","year":"2024","unstructured":"Hua Z, Wu Q, Yang Y, Liu S, Jennifer TG, Zhao D, Fang Y (2024) Essential roles of ellagic acid-to-urolithin converting bacteria in human health and health food industry: an updated review. Trends Food Sci Technol 151:104622. https:\/\/doi.org\/10.1016\/j.tifs.2024.104622","journal-title":"Trends Food Sci Technol"},{"key":"5541_CR64","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.neuro.2025.04.009","volume":"108","author":"A Devi","year":"2025","unstructured":"Devi A, Munagalasetty S, Kumar P et al (2025) Neurotoxicology urolithin improves \u03b1 -synuclein aggregation and DNMT1 expression in rotenone model of Parkinson\u2019s disease. Neurotoxicology 108:246\u2013262. https:\/\/doi.org\/10.1016\/j.neuro.2025.04.009","journal-title":"Neurotoxicology"},{"key":"5541_CR65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/jobm.200510600","volume":"46","author":"L Mingshu","year":"2006","unstructured":"Mingshu L, Kai Y, Qiang H, Dongying J (2006) Biodegradation of gallotannins and ellagitannins. J Basic Microbiol 46:68\u201384. https:\/\/doi.org\/10.1002\/jobm.200510600","journal-title":"J Basic Microbiol"},{"key":"5541_CR66","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1080\/10408398.2011.644643","volume":"54","author":"C Garcia-Mu\u00f1oz","year":"2014","unstructured":"Garcia-Mu\u00f1oz C, Vaillant F (2014) Metabolic fate of ellagitannins: implications for health, and research perspectives for innovative functional foods. Crit Rev Food Sci Nutr 54:1584\u20131598. https:\/\/doi.org\/10.1080\/10408398.2011.644643","journal-title":"Crit Rev Food Sci Nutr"},{"key":"5541_CR67","doi-asserted-by":"publisher","first-page":"16273","DOI":"10.1021\/acs.jafc.2c06585","volume":"70","author":"V Caballero","year":"2022","unstructured":"Caballero V, Est\u00e9vez M, Tom\u00e1s-Barber\u00e1n FA et al (2022) Biodegradation of punicalagin into ellagic acid by selected probiotic bacteria: a study of the underlying mechanisms by MS-based proteomics. J Agric Food Chem 70:16273\u201316285. https:\/\/doi.org\/10.1021\/acs.jafc.2c06585","journal-title":"J Agric Food Chem"},{"key":"5541_CR68","doi-asserted-by":"publisher","unstructured":"Liu Q, Liu S, Ye Q, Hou X, Yang G, Lu J, Hai Y, Shen J, et al. (2022) A novel Streptococcus thermophilus FUA329 isolated from human breast milk capable of producing urolithin a from ellagic acid. Foods 11(20):3280. https:\/\/doi.org\/10.3390\/foods11203280","DOI":"10.3390\/foods11203280"},{"key":"5541_CR69","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1039\/d2fo03957e","volume":"14","author":"CE Iglesias-Aguirre","year":"2023","unstructured":"Iglesias-Aguirre CE, Gonz\u00e1lez-Sarr\u00edas A, Cort\u00e9s-Mart\u00edn A et al (2023) In vivo administration of gut bacterial consortia replicates urolithin metabotypes A and B in a non-urolithin-producing rat model. Food Funct 14:2657\u20132667. https:\/\/doi.org\/10.1039\/d2fo03957e","journal-title":"Food Funct"},{"issue":"17","key":"5541_CR70","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.3390\/foods11172621","volume":"11","author":"H Mi","year":"2022","unstructured":"Mi H, Liu S, Hai Y, Yang G, Lu J, He F, Zhao Y, Xia M et al (2022) Lactococcus garvieae FUA009, a novel intestinal bacterium capable of producing the bioactive metabolite urolithin a from ellagic acid. Foods 11(17):2621. https:\/\/doi.org\/10.3390\/foods11172621","journal-title":"Foods"},{"key":"5541_CR71","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.1021\/acs.jafc.3c01062","volume":"71","author":"M Zhang","year":"2023","unstructured":"Zhang M, Cui S, Mao B et al (2023) Urolithin A produced by novel microbial fermentation possesses anti-aging effects by improving mitophagy and reducing reactive oxygen species in Caenorhabditis elegans. J Agric Food Chem 71:6348\u20136357. https:\/\/doi.org\/10.1021\/acs.jafc.3c01062","journal-title":"J Agric Food Chem"},{"key":"5541_CR72","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jff.2018.03.040","volume":"45","author":"P Gaya","year":"2018","unstructured":"Gaya P, Peirot\u00e9n \u00c1, Medina M, \u00c1lvarez I, Landete JM (2018) Bifidobacterium pseudocatenulatum INIA P815: the first bacterium able to produce urolithins A and B from ellagic acid. J Funct Foods 45:95\u201399. https:\/\/doi.org\/10.1016\/j.jff.2018.03.040","journal-title":"J Funct Foods"},{"key":"5541_CR73","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1039\/c4fo00092g","volume":"5","author":"MV Selma","year":"2014","unstructured":"Selma MV, Beltr\u00e1n D, Garc\u00eda-Villalba R et al (2014) Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food Funct 5:1779\u20131784. https:\/\/doi.org\/10.1039\/c4fo00092g","journal-title":"Food Funct"},{"key":"5541_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00203-024-03844-5","volume":"206","author":"HS Kim","year":"2024","unstructured":"Kim HS, Kim JS, Suh MK et al (2024) Gordonibacter faecis sp. nov., producing urolithin C from ellagic acid, isolated from feces of healthy Korean subjects. Arch Microbiol 206:1\u20138. https:\/\/doi.org\/10.1007\/s00203-024-03844-5","journal-title":"Arch Microbiol"},{"key":"5541_CR75","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1099\/ijs.0.055095-0","volume":"64","author":"MV Selma","year":"2014","unstructured":"Selma MV, Tom\u00e1s-Barber\u00e1n FA, Beltr\u00e1n D et al (2014) Gordonibacter urolithinfaciens sp. nov., a urolithin-producing bacterium isolated from the human gut. Int J Syst Evol Microbiol 64:2346\u20132352. https:\/\/doi.org\/10.1099\/ijs.0.055095-0","journal-title":"Int J Syst Evol Microbiol"},{"key":"5541_CR76","doi-asserted-by":"publisher","first-page":"11921","DOI":"10.1021\/acs.jafc.3c01675","volume":"71","author":"D Beltr\u00e1n","year":"2023","unstructured":"Beltr\u00e1n D, Frutos-Lis\u00f3n MD, Garc\u00eda-Villalba R et al (2023) NMR spectroscopic identification of urolithin G, a novel trihydroxy urolithin produced by human intestinal enterocloster species. J Agric Food Chem 71:11921\u201311928. https:\/\/doi.org\/10.1021\/acs.jafc.3c01675","journal-title":"J Agric Food Chem"},{"issue":"2","key":"5541_CR77","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1158\/1535-7163.MCT-18-0464","volume":"18","author":"TM Totiger","year":"2019","unstructured":"Totiger TM, Srinivasan S, Jala VR, Lamichhane P, Dosch AR, Gaidarski AA III, Joshi C, Rangappa S et al (2019) Urolithin A, a novel natural compound to target PI3K\/AKT\/mTOR pathway in pancreatic cancer. Mol Cancer Ther 18(2):301\u2013311. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0464","journal-title":"Mol Cancer Ther"},{"key":"5541_CR78","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1002\/mnfr.201600048","volume":"60","author":"W Zhang","year":"2016","unstructured":"Zhang W, Chen JH, Aguilera-Barrantes I et al (2016) Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-\u03b1-dependent gene expression. Mol Nutr Food Res 60:2387\u20132395. https:\/\/doi.org\/10.1002\/mnfr.201600048","journal-title":"Mol Nutr Food Res"},{"key":"5541_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.113628","volume":"272","author":"YZ Zhang","year":"2021","unstructured":"Zhang YZ, Zhang Y, Halemahebai G et al (2021) Urolithin A, a pomegranate metabolite, protects pancreatic \u03b2 cells from apoptosis by activating autophagy. J Ethnopharmacol 272:113628. https:\/\/doi.org\/10.1016\/j.jep.2020.113628","journal-title":"J Ethnopharmacol"},{"key":"5541_CR80","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11418-024-01821-2","volume":"78","author":"H Yang","year":"2024","unstructured":"Yang H, Wu B, yang Q et al (2024) Urolithin C suppresses colorectal cancer progression via the AKT\/mTOR pathway. J Nat Med 78:887\u2013900. https:\/\/doi.org\/10.1007\/s11418-024-01821-2","journal-title":"J Nat Med"},{"key":"5541_CR81","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1007\/s00210-023-02492-8","volume":"396","author":"J Xu","year":"2023","unstructured":"Xu J, Tian H, Ji Y et al (2023) Urolithin C reveals anti-NAFLD potential via AMPK-ferroptosis axis and modulating gut microbiota. Naunyn Schmiedebergs Arch Pharmacol 396:2687\u20132699. https:\/\/doi.org\/10.1007\/s00210-023-02492-8","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5541_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154867","volume":"116","author":"J Li","year":"2023","unstructured":"Li J, Liao R, Zhang S, Weng H, Liu Y, Tao T, Yu F, Li G et al (2023) Promising remedies for cardiovascular disease: natural polyphenol ellagic acid and its metabolite urolithins. Phytomedicine 116:154867. https:\/\/doi.org\/10.1016\/j.phymed.2023.154867","journal-title":"Phytomedicine"},{"key":"5541_CR83","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41430-021-00950-1","volume":"76","author":"A Singh","year":"2022","unstructured":"Singh A, D\u2019Amico D, Andreux PA et al (2022) Direct supplementation with Uurolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population. Eur J Clin Nutr 76:297\u2013308. https:\/\/doi.org\/10.1038\/s41430-021-00950-1","journal-title":"Eur J Clin Nutr"},{"key":"5541_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2023.137953","volume":"437","author":"Y Yang","year":"2024","unstructured":"Yang Y, Lee PK, Wong HC, Zhao D (2024) Oral supplementation of Gordonibacter urolithinfaciens promotes ellagic acid metabolism and urolithin bioavailability in mice. Food Chem 437:137953. https:\/\/doi.org\/10.1016\/j.foodchem.2023.137953","journal-title":"Food Chem"},{"key":"5541_CR85","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbi.2018.02.005","volume":"70","author":"MF Sun","year":"2018","unstructured":"Sun MF, Zhu YL, Zhou ZL, Jia X-B, Xu Y-D, Yang Q, Cui C, Shen Y-Q (2018) Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson\u2019s disease mice: gut microbiota, glial reaction and TLR4\/TNF-\u03b1 signaling pathway. Brain Behav Immun 70:48\u201360. https:\/\/doi.org\/10.1016\/j.bbi.2018.02.005","journal-title":"Brain Behav Immun"},{"key":"5541_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40168-021-01107-9","volume":"9","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Ning J, Bao Xq et al (2021) Fecal microbiota transplantation protects rotenone-induced Parkinson\u2019s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome 9:1\u201327. https:\/\/doi.org\/10.1186\/s40168-021-01107-9","journal-title":"Microbiome"},{"key":"5541_CR87","doi-asserted-by":"publisher","first-page":"100128","DOI":"10.1016\/j.medmic.2025.100128","volume":"25","author":"S Shekar","year":"2025","unstructured":"Shekar S, Venkatachalapathy R, Jayaraman A, Sai Supra Siddhu N (2025) Fecal microbiota transplantation for Parkinson\u2019s disease: a systematic review of clinical evidence. Med Microecolgy 25:100128. https:\/\/doi.org\/10.1016\/j.medmic.2025.100128","journal-title":"Med Microecolgy"},{"key":"5541_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000016163","volume":"98","author":"H Huang","year":"2019","unstructured":"Huang H, Xu H, Luo Q et al (2019) Fecal microbiota transplantation to treat Parkinson\u2019s disease with constipation: a case report. Medicine (United States) 98:1\u20134. https:\/\/doi.org\/10.1097\/MD.0000000000016163","journal-title":"Medicine (United States)"},{"key":"5541_CR89","doi-asserted-by":"publisher","first-page":"1104759","DOI":"10.3389\/fneur.2023.1104759","volume":"14","author":"HL Dupont","year":"2023","unstructured":"Dupont HL, Suescun J, Jiang Z et al (2023) Fecal microbiota transplantation in Parkinson\u2019s disease \u2014 a placebo-controlled clinical pilot study. Front Neurol 14:1104759","journal-title":"Front Neurol"},{"key":"5541_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfutfo.2025.02.013","author":"Z Hua","year":"2025","unstructured":"Hua Z, Gong X, Chi K et al (2025) Enhancing urolithin A yield by Limosilactobacillus fermentum FUA033 in human gut microbiota across three urolithin-metabotype mice. J Future Foods. https:\/\/doi.org\/10.1016\/j.jfutfo.2025.02.013","journal-title":"J Future Foods"},{"key":"5541_CR91","doi-asserted-by":"publisher","unstructured":"Collier TJ, Kanaan NM, Kordower JH (2018) Aging and Parkinson\u2019s disease: different sides of the same. Aging 32:983\u2013990.  https:\/\/doi.org\/10.1002\/mds.27037","DOI":"10.1002\/mds.27037"},{"key":"5541_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02253-4","author":"X Xu","year":"2025","unstructured":"Xu X, Pang Y (2025) Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-025-02253-4","journal-title":"Signal Transduct Target Ther"},{"key":"5541_CR93","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s13311-019-00753-0","volume":"16","author":"P Chen","year":"2019","unstructured":"Chen P, Chen F, Lei J et al (2019) Activation of the miR-34a-mediated SIRT1\/mTOR signaling pathway by urolithin A attenuates d-galactose-induced brain aging in mice. Neurotherapeutics 16:1269\u20131282. https:\/\/doi.org\/10.1007\/s13311-019-00753-0","journal-title":"Neurotherapeutics"},{"key":"5541_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2021.768097","volume":"12","author":"P Chen","year":"2021","unstructured":"Chen P, Chen F, Lei J et al (2021) The gut microbiota metabolite urolithin B improves cognitive deficits by inhibiting Cyt C-mediated apoptosis and promoting the survival of neurons through the PI3K pathway in aging mice. Front Pharmacol 12:1\u201321. https:\/\/doi.org\/10.3389\/fphar.2021.768097","journal-title":"Front Pharmacol"},{"key":"5541_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113151","volume":"142","author":"P Chen","year":"2024","unstructured":"Chen P, Wu L, Lei J, Chen F, Feng L, Liu G, Zhou B (2024) The ellagitannin metabolite urolithin C attenuated cognitive impairment by inhibiting neuroinflammation via downregulation of MAPK \/ NF-kB signaling pathways in aging mice. Int Immunopharmacol 142:113151. https:\/\/doi.org\/10.1016\/j.intimp.2024.113151","journal-title":"Int Immunopharmacol"},{"key":"5541_CR96","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1353-8020(09)70004-5","volume":"15","author":"T Nagatsua","year":"2009","unstructured":"Nagatsua T, Sawadab M (2009) L-dopa therapy for Parkinson\u2019s disease: past, present, and future. Parkinsonism Relat Disord 15:3\u20138. https:\/\/doi.org\/10.1016\/S1353-8020(09)70004-5","journal-title":"Parkinsonism Relat Disord"},{"key":"5541_CR97","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00726-005-0162-4","volume":"28","author":"RM Kostrzewa","year":"2005","unstructured":"Kostrzewa RM, Nowak P, Kostrzewa JP et al (2005) Peculiarities of L-DOPA treatment of Parkinson\u2019s disease. Amino Acids 28:157\u2013164. https:\/\/doi.org\/10.1007\/s00726-005-0162-4","journal-title":"Amino Acids"},{"key":"5541_CR98","doi-asserted-by":"publisher","unstructured":"Deane K, Spieker S, Ce C et al (2004) Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson\u2019s disease (Review). https:\/\/doi.org\/10.1002\/14651858.CD004554.pub2.www.cochranelibrary.com","DOI":"10.1002\/14651858.CD004554.pub2.www.cochranelibrary.com"},{"key":"5541_CR99","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00702-023-02623-8","volume":"130","author":"M Regensburger","year":"2023","unstructured":"Regensburger M, Ip CW, Kohl Z et al (2023) Clinical benefit of MAO-B and COMT inhibition in Parkinson\u2019s disease: practical considerations. J Neural Transm 130:847\u2013861. https:\/\/doi.org\/10.1007\/s00702-023-02623-8","journal-title":"J Neural Transm"},{"key":"5541_CR100","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2478\/jccm-2019-0024","volume":"5","author":"A Lahlou","year":"2019","unstructured":"Lahlou A, Benlamkaddem S, Berdai MA, Harandou M (2019) Accidental Modopar\u00a9 poisoning in a two-year-old child: a case report. J Crit Care Med 5:157\u2013160. https:\/\/doi.org\/10.2478\/jccm-2019-0024","journal-title":"J Crit Care Med"},{"issue":"8","key":"5541_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103740","volume":"9","author":"BB Nankova","year":"2014","unstructured":"Nankova BB, Agarwal R, MacFabe DF, La Gamma EF (2014) Enteric bacterial metabolites propionic and butyric acid modulate gene expression, including CREB-dependent catecholaminergic neurotransmission, in PC12 cells - possible relevance to autism spectrum disorders. PLoS ONE 9(8):e103740. https:\/\/doi.org\/10.1371\/journal.pone.0103740","journal-title":"PLoS ONE"},{"key":"5541_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.108963","volume":"207","author":"J Qiu","year":"2022","unstructured":"Qiu J, Chen Y, Zhuo J, Zhang Li, Liu J, Wang B, Sun D, Yu S, Lou H (2022) Urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson\u2019s disease model. Neuropharmacology 207:108963. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.108963","journal-title":"Neuropharmacology"},{"key":"5541_CR103","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1039\/d1fo02534a","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Jiang J, Qiu J et al (2022) Urolithin A protects dopaminergic neurons in experimental models of Parkinson\u2019s disease by promoting mitochondrial biogenesis through the SIRT1\/PGC-1\u03b1 signaling pathway. Food Funct 13:375\u2013385. https:\/\/doi.org\/10.1039\/d1fo02534a","journal-title":"Food Funct"},{"key":"5541_CR104","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0161-813X(03)00090-1","volume":"25","author":"WJ Burke","year":"2004","unstructured":"Burke WJ, Li SW, Chung HD et al (2004) Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 25:101\u2013115. https:\/\/doi.org\/10.1016\/S0161-813X(03)00090-1","journal-title":"Neurotoxicology"},{"key":"5541_CR105","doi-asserted-by":"publisher","unstructured":"Singh R, Chandrashekharappa S, Vemula PK, Haribabu B, Jala VR (2020) Microbial metabolite urolithin B inhibits recombinant human monoamine oxidase A enzyme. Metabolites 10(6):258. https:\/\/doi.org\/10.3390\/metabo10060258","DOI":"10.3390\/metabo10060258"},{"key":"5541_CR106","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/j.1471-4159.1983.tb08123.x","volume":"40","author":"CJ Fowler","year":"1983","unstructured":"Fowler CJ, Benedetti MS (1983) The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone. J Neurochem 40:1534\u20131541. https:\/\/doi.org\/10.1111\/j.1471-4159.1983.tb08123.x","journal-title":"J Neurochem"},{"key":"5541_CR107","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s12276-021-00646-3","volume":"53","author":"HU Cho","year":"2021","unstructured":"Cho HU, Kim S, Sim J et al (2021) Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis. Exp Mol Med 53:1148\u20131158. https:\/\/doi.org\/10.1038\/s12276-021-00646-3","journal-title":"Exp Mol Med"},{"key":"5541_CR108","doi-asserted-by":"publisher","unstructured":"C\u00e1sedas G, Les F, Choya-Foces C, Hugo M, L\u00f3pez V (2020) The metabolite urolithin-A ameliorates oxidative stress in neuro-2a cells, becoming a potential neuroprotective agent. Antioxidants (Basel, Switzerland) 9(2):177. https:\/\/doi.org\/10.3390\/antiox9020177","DOI":"10.3390\/antiox9020177"},{"key":"5541_CR109","doi-asserted-by":"publisher","unstructured":"Carballo-Carbajal I, Laguna A, Romero-Gim\u00e9nez J, Cuadros T, Bov\u00e9 J, Martinez-Vicente M, Parent A, Gonzalez-Sepulveda M et al (2019) Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson\u2019s disease pathogenesis. Nat Commun 10(1):973. https:\/\/doi.org\/10.1038\/s41467-019-08858-y","DOI":"10.1038\/s41467-019-08858-y"},{"key":"5541_CR110","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/iub.2654","volume":"75","author":"FA Zucca","year":"2023","unstructured":"Zucca FA, Capucciati A, Bellei C et al (2023) Neuromelanins in brain aging and Parkinson\u2019s disease: synthesis, structure, neuroinflammatory, and neurodegenerative role. IUBMB Life 75:55\u201365. https:\/\/doi.org\/10.1002\/iub.2654","journal-title":"IUBMB Life"},{"key":"5541_CR111","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/1028415X.2017.1360558","volume":"22","author":"NA DaSilva","year":"2019","unstructured":"DaSilva NA, Nahar PP, Ma H et al (2019) Pomegranate ellagitannin-gut microbial-derived metabolites, urolithins, inhibit neuroinflammation in vitro. Nutr Neurosci 22:185\u2013195. https:\/\/doi.org\/10.1080\/1028415X.2017.1360558","journal-title":"Nutr Neurosci"},{"key":"5541_CR112","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4162\/nrp.2020.14.1.3","volume":"14","author":"KB Kim","year":"2020","unstructured":"Kim KB, Lee S, Kim JH (2020) Neuroprotective effects of urolithin a on H2O2-induced oxidative stress-mediated apoptosis in SK-N-MC cells. Nutr Res Pract 14:3\u201311. https:\/\/doi.org\/10.4162\/nrp.2020.14.1.3","journal-title":"Nutr Res Pract"},{"key":"5541_CR113","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1021\/acs.jafc.7b03285","volume":"66","author":"J Xu","year":"2018","unstructured":"Xu J, Yuan C, Wang G et al (2018) Urolithins attenuate LPS-induced neuroinflammation in BV2 microglia via MAPK, Akt, and NF-\u03baB signaling pathways. J Agric Food Chem 66:571\u2013580. https:\/\/doi.org\/10.1021\/acs.jafc.7b03285","journal-title":"J Agric Food Chem"},{"key":"5541_CR114","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.phymed.2018.06.032","volume":"55","author":"G Lee","year":"2019","unstructured":"Lee G, Park JS, Lee EJ et al (2019) Anti-inflammatory and antioxidant mechanisms of urolithin B in activated microglia. Phytomedicine 55:50\u201357. https:\/\/doi.org\/10.1016\/j.phymed.2018.06.032","journal-title":"Phytomedicine"},{"issue":"11","key":"5541_CR115","doi-asserted-by":"publisher","first-page":"103804","DOI":"10.1016\/j.sjbs.2023.103804","volume":"30","author":"AG Revankar","year":"2023","unstructured":"Revankar AG, Bagewadi ZK, Shaikh IA, Mannasaheb BA, Ghoneim MM, Khan AA, Asdaq SMB (2023) In-vitro and computational analysis of urolithin-A for anti-inflammatory activity on cyclooxygenase 2 (COX-2). Saudi J Biol Sci 30(11):103804. https:\/\/doi.org\/10.1016\/j.sjbs.2023.103804","journal-title":"Saudi J Biol Sci"},{"key":"5541_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a024091","volume":"8","author":"J Burr\u00e9","year":"2018","unstructured":"Burr\u00e9 J, Sharma M, S\u00fcdhof TC (2018) Cell biology and pathophysiology of \u03b1-synuclein. Cold Spring Harb Perspect Med 8:1\u201328. https:\/\/doi.org\/10.1101\/cshperspect.a024091","journal-title":"Cold Spring Harb Perspect Med"},{"key":"5541_CR117","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1007\/s00018-017-2541-x","volume":"74","author":"V Tapias","year":"2017","unstructured":"Tapias V, Hu X, Luk KC et al (2017) Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. Cell Mol Life Sci 74:2851\u20132874. https:\/\/doi.org\/10.1007\/s00018-017-2541-x","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"5541_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (2023) Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14(3):176. https:\/\/doi.org\/10.1038\/s41419-023-05672-9","journal-title":"Cell Death Dis"},{"key":"5541_CR119","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5607\/en23007","volume":"32","author":"BJ Kim","year":"2023","unstructured":"Kim BJ, Noh HR, Jeon H, Park SM (2023) Monitoring \u03b1-synuclein aggregation induced by preformed \u03b1-synuclein fibrils in an in vitro model system. Exp Neurobiol 32:147\u2013156. https:\/\/doi.org\/10.5607\/en23007","journal-title":"Exp Neurobiol"},{"key":"5541_CR120","doi-asserted-by":"publisher","DOI":"10.3791\/59758","author":"JR Patterson","year":"2019","unstructured":"Patterson JR, Polinski NK, Duffy MF et al (2019) Generation of alpha-synuclein preformed fibrils from monomers and use in vivo. J Vis Exp. https:\/\/doi.org\/10.3791\/59758","journal-title":"J Vis Exp"},{"key":"5541_CR121","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1110\/ps.052048706","volume":"15","author":"M Bisaglia","year":"2006","unstructured":"Bisaglia M, Trolio A, Bellanda M et al (2006) Structure and topology of the non-amyloid-\u03b2 component fragment of human \u03b1-synuclein bound to micelles: implications for the aggregation process. Protein Sci 15:1408\u20131416. https:\/\/doi.org\/10.1110\/ps.052048706","journal-title":"Protein Sci"},{"key":"5541_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2019.00540","volume":"13","author":"EN Anderson","year":"2020","unstructured":"Anderson EN, Hirpa D, Zheng KH et al (2020) The non-amyloidal component region of \u03b1-synuclein is important for \u03b1-synuclein transport within axons. Front Cell Neurosci 13:1\u201319. https:\/\/doi.org\/10.3389\/fncel.2019.00540","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"5541_CR123","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbrc.2007.01.043","volume":"354","author":"JJM Hoozemans","year":"2007","unstructured":"Hoozemans JJM, Rozemuller JM, Scheper W (2007) Activation of the unfolded protein response in Parkinson\u2019s disease. Biochem Biophys Res Commun 354(3):707\u2013711. https:\/\/doi.org\/10.1016\/j.bbrc.2007.01.043","journal-title":"Biochem Biophys Res Commun"},{"key":"5541_CR124","doi-asserted-by":"publisher","unstructured":"Rozp\u0119dek-Kami\u0144ska W, Siwecka N, Wawrzynkiewicz A, Wojtczak R, Pytel D, Diehl JA, Majsterek I (2020) The PERK-dependent molecular mechanisms as a novel therapeutic target for neurodegenerative diseases.\u00a0Int J Mol Sci 21(6):2108. https:\/\/doi.org\/10.3390\/ijms21062108","DOI":"10.3390\/ijms21062108"},{"key":"5541_CR125","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.brainres.2017.02.021","volume":"1662","author":"T Baluchnejadmojarad","year":"2017","unstructured":"Baluchnejadmojarad T, Rabiee N, Zabihnejad S, Roghani M (2017) Ellagic acid exerts protective effect in intrastriatal 6-hydroxydopamine rat model of Parkinson\u2019s disease: possible involvement of ER\u03b2\/Nrf2\/HO-1 signaling. Brain Res 1662:23\u201330. https:\/\/doi.org\/10.1016\/j.brainres.2017.02.021","journal-title":"Brain Res"},{"key":"5541_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci11091127","volume":"11","author":"M Kujawska","year":"2021","unstructured":"Kujawska M, Jourdes M, Witucki \u0141 et al (2021) Pomegranate juice ameliorates dopamine release and behavioral deficits in a rat model of Parkinson\u2019s disease. Brain Sci 11:1\u20139. https:\/\/doi.org\/10.3390\/brainsci11091127","journal-title":"Brain Sci"},{"issue":"7","key":"5541_CR127","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1089\/ars.2012.5149","volume":"20","author":"M Mittal","year":"2014","unstructured":"Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB (2014) Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal 20(7):1126\u20131167. https:\/\/doi.org\/10.1089\/ars.2012.5149","journal-title":"Antioxid Redox Signal"},{"key":"5541_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105700","volume":"168","author":"F Weiss","year":"2022","unstructured":"Weiss F, Labrador-Garrido A, Dzamko N, Halliday G (2022) Immune responses in the Parkinson\u2019s disease brain. Neurobiol Dis 168:105700. https:\/\/doi.org\/10.1016\/j.nbd.2022.105700","journal-title":"Neurobiol Dis"},{"key":"5541_CR129","doi-asserted-by":"publisher","unstructured":"Nagatsu T, Sawada M (2007) Biochemistry of postmortem brains in Parkinson\u2019s disease: historical overview and future prospects. J Neural Transm Suppl 113\u2013120. https:\/\/doi.org\/10.1007\/978-3-211-73574-9_14","DOI":"10.1007\/978-3-211-73574-9_14"},{"key":"5541_CR130","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ana.410240415","volume":"24","author":"PL McGeer","year":"1988","unstructured":"McGeer PL, Itagaki S, Akiyama H, McGeer EG (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24:574\u2013576. https:\/\/doi.org\/10.1002\/ana.410240415","journal-title":"Ann Neurol"},{"key":"5541_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.108963","volume":"207","author":"J Qiu","year":"2022","unstructured":"Qiu J, Chen Y, Zhuo J et al (2022) Neuropharmacology urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson\u2019s disease model. Neuropharmacology 207:108963. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.108963","journal-title":"Neuropharmacology"},{"key":"5541_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun SC (2017) NF-\u03baB signaling in inflammation. Signal Transduct Target Ther 2:17023. https:\/\/doi.org\/10.1038\/sigtrans.2017.23","journal-title":"Signal Transduct Target Ther"},{"key":"5541_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph18010068","volume":"18","author":"AM Toney","year":"2021","unstructured":"Toney AM, Albusharif M, Works D et al (2021) Differential effects of whole red raspberry polyphenols and their gut metabolite urolithin a on neuroinflammation in BV-2 microglia. Int J Environ Res Public Health 18:1\u201311. https:\/\/doi.org\/10.3390\/ijerph18010068","journal-title":"Int J Environ Res Public Health"},{"key":"5541_CR134","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.toxrep.2018.02.017","volume":"5","author":"F Firdaus","year":"2018","unstructured":"Firdaus F, Zafeer MF, Anis E et al (2018) Ellagic acid attenuates arsenic induced neuro-inflammation and mitochondrial dysfunction associated apoptosis. Toxicol Rep 5:411\u2013417. https:\/\/doi.org\/10.1016\/j.toxrep.2018.02.017","journal-title":"Toxicol Rep"},{"key":"5541_CR135","doi-asserted-by":"publisher","first-page":"114811","DOI":"10.1016\/j.bbr.2023.114811","volume":"459","author":"MF Yao","year":"2024","unstructured":"Yao MF, Dang T, Wang HJ et al (2024) Mitochondrial homeostasis regulation: a promising therapeutic target for Parkinson\u2019s disease. Behav Brain Res 459:114811. https:\/\/doi.org\/10.1016\/j.bbr.2023.114811","journal-title":"Behav Brain Res"},{"key":"5541_CR136","doi-asserted-by":"publisher","first-page":"8136","DOI":"10.1007\/s12035-019-01654-1","volume":"56","author":"MJ Ramirez-Moreno","year":"2019","unstructured":"Ramirez-Moreno MJ, Duarte-Jurado AP, Gopar-Cuevas Y et al (2019) Autophagy stimulation decreases dopaminergic neuronal death mediated by oxidative stress. Mol Neurobiol 56:8136\u20138156. https:\/\/doi.org\/10.1007\/s12035-019-01654-1","journal-title":"Mol Neurobiol"},{"key":"5541_CR137","doi-asserted-by":"publisher","unstructured":"Stefanoni G, Sala G, Tremolizzo L et al (2012) Role of autophagy in Parkinson\u2019s disease. Autophagy: Principles, Regulation and Roles in Disease 243\u2013264. https:\/\/doi.org\/10.2174\/0929867325666180226094351","DOI":"10.2174\/0929867325666180226094351"},{"key":"5541_CR138","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1101\/gad.1599207","volume":"21","author":"N Mizushima","year":"2007","unstructured":"Mizushima N (2007) Autophagy: process and function. Genes Dev 21:2861\u20132873. https:\/\/doi.org\/10.1101\/gad.1599207","journal-title":"Genes Dev"},{"key":"5541_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413398","volume":"22","author":"MT Ardah","year":"2021","unstructured":"Ardah MT, Eid N, Kitada T, Haque ME (2021) Ellagic acid prevents \u03b1-synuclein aggregation and protects sh-sy5y cells from aggregated \u03b1-synuclein-induced toxicity via suppression of apoptosis and activation of autophagy. Int J Mol Sci 22:13398. https:\/\/doi.org\/10.3390\/ijms222413398","journal-title":"Int J Mol Sci"},{"key":"5541_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu16010085","volume":"16","author":"N Radwan","year":"2024","unstructured":"Radwan N, Khan E, Ardah MT et al (2024) Ellagic acid prevents \u03b1-synuclein spread and mitigates toxicity by enhancing autophagic flux in an animal model of Parkinson\u2019s disease. Nutrients 16:1\u201318. https:\/\/doi.org\/10.3390\/nu16010085","journal-title":"Nutrients"},{"issue":"6","key":"5541_CR141","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ceb.2004.09.012","volume":"16","author":"RV Rao","year":"2004","unstructured":"Rao RV, Bredesen DE (2004) Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr Opin Cell Biol 16(6):653\u2013662. https:\/\/doi.org\/10.1016\/j.ceb.2004.09.012","journal-title":"Curr Opin Cell Biol"},{"key":"5541_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20030728","volume":"20","author":"Z Zhu","year":"2019","unstructured":"Zhu Z, Yang C, Iyaswamy A et al (2019) Balancing mTOR signaling and autophagy in the treatment of Parkinson\u2019s disease. Int J Mol Sci 20:1\u201315. https:\/\/doi.org\/10.3390\/ijms20030728","journal-title":"Int J Mol Sci"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05541-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05541-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05541-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:07:55Z","timestamp":1764180475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05541-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":142,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5541"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05541-w","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}